ScripMergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S
ScripLeading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
ScripSentiment around initial public offerings (IPOs) appears to be slowly recovering in South Korea as the market stabilizes somewhat amid ongoing political uncertainties at home and abroad. A couple of b